title: The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study.
abstract: Studies with haemophilia A (HA) patients have shown burden in health-related quality of life (HRQOL) when compared with general population norms. In the current study, HA patients' SF-36v2 health survey scores were compared with general population norms and to patients with other chronic conditions. The impact of target joints (TJs) on HRQOL was also examined. The sample was a subset of HA patients enrolled in the Post-Authorization Safety Surveillance (PASS) programme: a prospective open-label study in which ADVATE [Antihaemophilic Factor (Recombinant), Plasma/Albumin-Free Method] was prescribed. A total of 205 patients who were ≥ 18 years old and had SF-36v2 baseline scores were selected for this study. To measure the burden of HA on HRQOL, manova analyses compared these SF-36v2 scores to age- and gender-matched general population US and EU norms and to patients from other chronic condition groups. manova and correlational analyses examined the relations among TJ, age and SF-36v2 scores. Comparisons with general population norms confirm that HA negatively impacts physical, but not mental, HRQOL. Comparison with other chronic conditions shows the physical burden of HA is greater than for chronic back pain but similar to diabetes and rheumatoid arthritis, while the mental burden of HA is less than for all three patient groups. The presence of TJs was negatively associated with physical HRQOL, although this association was much larger for older patients (45+ years) than for younger ones. Physical, but not mental, HRQOL is diminished in HA patients. Target joints are associated with lower physical HRQOL, although this effect is moderated by age.
authors.affiliation: Vivantes - Klinikum in Friedrichhain, Klinik fuer Innere Medizin, Haemophiliezentrum, Berlin, Germany. robert.klamroth@vivantes.de
authors.forename: R
authors.initials: R
authors.lastname: Klamroth
authors.forename: H
authors.initials: H
authors.lastname: Pollmann
authors.forename: C
authors.initials: C
authors.lastname: Hermans
authors.forename: A
authors.initials: A
authors.lastname: Faradji
authors.forename: A S
authors.initials: AS
authors.lastname: Yarlas
authors.forename: J D
authors.initials: JD
authors.lastname: Epstein
authors.forename: B M
authors.initials: BM
authors.lastname: Ewenstein
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D017281:Cost of Illness; D005169:Factor VIII / Q000627:therapeutic use; D005260:Female; D006304:Health Status; D006306:Health Surveys; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology* / Q000523:psychology*; D006801:Humans; D007592:Joint Diseases / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011788:Quality of Life; D011795:Surveys and Questionnaires; D055815:Young Adult
chemical_list: D005169:Factor VIII